Considerations For Pursuing Accelerated Approval In Oncology Indications
For many years, sponsors in the US have been able to apply for Accelerated Approval from regulators based on a surrogate endpoint. This approach is intended to speed products to market that treat serious or life-threatening conditions and that offer a benefit over current treatments. Similarly, in the EU, a conditional marketing authorization can be granted to drugs that fill an unmet need and treat rare or life-threatening diseases using less clinical data than would typically be required. Both the Food and Drug Administration (FDA) and European Medicines Agency (EMA) require that the sponsor complete certain post-authorization study obligations. The pathway for Accelerated Approval is well established in these markets, and industry experts have gained considerable experience in guiding products through the process.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.